RE: What's next? Why is everyone going nuts over the 3 patients treated with the safety dose?
That is not a relatable example bjoe. The way I see it, this is as if the doctor preescribes me antibiotics that are half the therapeutic dose. Obviously if I don't heal is not because of anything wrong in the medicine. We were testing safety and tolerability. After 3 months everybody got turned on with a cancer free scenario, but that was a gift, not a given.
This -50 is subject to all the invenstors that chipped in to ride a supernova, and without the miracle are dropping cheap shares for the longs to bargain. It makes 0 sense, besides a fairy tale level of expectations.
I mean, we are starting Phase II!
The key now is the development of the 4th patient over the next 3 months (too many eggs in one basket)*, the enrollment and treatment of the following ones, and how is all this operation going to be financed. We are in a fragile moment, strategical thinking for the next months should have been put in place to get us through this crash. We are going to spend some time in the .10s...
Cheers.
*It is not unreasonable to think that he/she might suffer recurrence, since the initial success estimations from the clinical team were close to 1 out of 3.
bionicjoe wrote: What's next?
Some posters would do well to stop attempting to trivialize the seriousness of today's PR. At the heart of the matter is the fact that the science did not work to prevent cancer recurrence. I'm not talking about striking down potentially deadly visible tumors but destroying for good the less demanding microscopic cancer cells. The last couple of days I've been using the analogy that you need to prove you can make it across the length of the pool before telling everyone you can swim the English Channel in record time. It would appear they didn't even make it to the end of the pool. Some are putting their faith for a comeback on the possibility the results were skewered by cancer cells migrating from another part of the body. Could be but why then did the PR use the vague term possibility and not probability? It still doesn't account for the fact that the researchers were well aware of the history of all 4 patients and proceeded with the treatment anyway. One could conclude that the experts didn't find cancer cell migration a worrisome enough issue. IMO, RW should not have bowed to pressure to release such early data. Maybe he had no choice but the results for the sp and perception of the science speak for themselves. What next? Pick up the pieces, re-finance the company at the best PP price he can squeeze out the capital markets and carry on at the sp valuation the market see's fit.